Rivaroxaban

Description:

API nomen est scriptor indication specification US DMF  EU DMF  BOLETUS
Rivaroxaban anticoagulant In Domus, TDP    

Product Detail

Product Tags

FRUCTUS SINGULA

Maecenas vitae

Rivaroxaban, oxo-V-N - [[(5S) -2 oxo-3- [4 (oxomorpholin-III-IV-y ') phenyl] -1,3 oxazolidin-V-y-] yl] II-thiophene -carboxamide, est potentior parva-Xa moleculo Matrix elementum quod est in sanguinem COAGULUM factor discrimine extremo, ad viam enim in generatione fit thrombin et quid ibi concreti formatione. Rivaroxaban ligat in sinum Tyr288 in S1 et elementum et Xa per conuersationem Tyr288 chlorothiophene medietatem de CHLORUM substituent. Quod praeceptum convertitur (= koff 5x10-3s-I) celeri (= kon 1.7x107 mol explorabatur / i I-I-s) et eiusdem collationem sub-dependens modo (Reg nmol = 0.4 / L). Rivaroxaban curatio est currently de VTE ad studium desit, ne cardiovasculares eventus in coronarius syndrome patientibus acuti, ne plaga in aegris cum atrial fibrillation.

Reference

Petrus Perzborn, Susanne Roehrig Alexander Straub Dagmar Kubitza, George Mueck et Volker Laux. Rivaroxaban: novi factor oris Xa inhibitor. Arterioscler Thromb Vasc Gen MMX, XXX (III): 376-381

Description

Rivaroxaban (BAV 59-7939) est summe potens;Triticum electionem selectivam, et recta XA (FXa) Matrix, achieving quaestum fortis in potentia, anti-FXa (IC50 0,7 m, m Reg 0,4).

 

In vitro

Rivaroxaban (BAV 59-7939) est oris, Factor recta XA (FXa) Matrix enim ne et curatio progressio in arteriarum atque venarum thrombosis. Rivaroxaban inhibits certatim homines FXa (Reg 0,4 m) apud> 000 X septiformem selectivity maior quam alia serine proteases; et etiam nia prothrombinase actio (IC50 Nm 2.1). In endogenous inhibits Rivaroxaban FXa multo fortius hominibus, uenatibus plasma (IC50 XXI m) quam plasma rat (m IC50 CCXC). Hoc plasma monstrat anticoagulant effectus in humanum, duplicando ultimi temporis prothrombin (TP Allelúia) thromboplastin suaque vi movet ex parte ad tempora et 0.23 0.69μM, respectively.

 

Rivaroxaban (BAV 59-7939) est potentior et electionem selectivam, actio et bonum in vivo optimum est recta FXa precursor bioavailability oris. Rivaroxaban (BAV 59-7939), IV, administratum per bolus thrombus ante inductione, thrombus reduces formation (ED50 0.1 mg / kg), FXa vetat obscura et quodammodo continuare PT dependenter dose. PT, FXa sunt affectus est cum ignominia in ED50 (1.8-ovili pecus et incremento XXXII% præceptum, respective). In 0.3 mg / kg (dose ducens ad completum fere inhibitionis de thrombus formation), moderate Rivaroxaban per patientiam sustentatur PT (3.2±0.5-ovili) deiciunt impediuntque FXa actio (LXV±III%).

 

storage

pulveris

-20 ° C

III annis
 

IV ° F

Annis II
In solvent

-80 ° C

VI mensibus
 

-20 ° C

I mensis

eget compages

Rivaroxaban

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

rogationem 18 Aestimatio qualis Constantia quae probatus projects 4, et 6 projects sub consilio.

Quality management2

Qualis international venditio procuratio ratio provecta iam posuit fundamentum.

Quality management3

Qualis vigilantia fugit per totum vitae cursum ad curare quale productum est ac medicinales effectus. 

Quality management4

Demandis regulatory Negotiis professio bigas species sustinet et adnotatione durante application.

PROLATIO MAGISTERIUM

cpf5
cpf6

Korea Countec packaging linea Bottled

cpf7
cpf8

Taiwan CVC packaging linea Bottled

cpf9
cpf10

CAM packaging linea Italia Board

cpf11

Fette artans German Apparatus

cpf12

Iaponia Viswill Traba Detector

cpf14-1

Des Control Room

SOCIUS

internationalis cooperante
International cooperation
domesticis cooperante
Domestic cooperation

  • priorem:
  • Deinde:

  • Dimitte nobis scribere Read more